Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CTNNB1 |
Variant | T41A |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | CTNNB1 T41A lies within a Gsk3b phosphorylation site of the Ctnnb1 protein (UniProt.org). T41A confers a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 and increased Ctnnb1-dependent transcription (PMID: 10698519, PMID: 10487827, PMID: 12200448). |
Associated Drug Resistance | |
Category Variants Paths |
CTNNB1 mutant CTNNB1 act mut CTNNB1 T41A |
Transcript | NM_001098210.2 |
gDNA | chr3:g.41224633A>G |
cDNA | c.121A>G |
Protein | p.T41A |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_047447479.1 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
NM_001098209.2 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
XM_017005738.1 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
XM_047447480.1 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
XM_005264886 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
XM_024453357.1 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
XM_047447478.1 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
XM_006712985.1 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
XM_047447481.1 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
NM_001904 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
XM_024453356.2 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
XM_024453358.1 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
XM_047447477.1 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
XM_017005738.2 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
NM_001098210.2 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
XM_017005738 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
NM_001098210.1 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
NM_001098210 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
NM_001098209 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
XM_006712985.2 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
NM_001904.3 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
NM_001098209.1 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
XM_047447483.1 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
XM_024453356.1 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
NM_001904.4 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
XM_006712985 | chr3:g.41224633A>G | c.121A>G | p.T41A | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04851119 | Phase Ib/II | BC2059 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Recruiting | USA | 0 |